Bristol-Myers Squibb and Array BioPharma to study new cancer therapy

Bristol-Myers Squibb has announced a new cancer-focused research collaboration with Array BioPharma.

The companies will investigate the safety, tolerability and efficacy of Array's investigational MEK inhibitor binimetinib in combination with Bristol-Myers Squibb's Opdivo and Yervoy as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumours.

A phase I/II study will be carried out to establish recommended dose regimens for further study, while also exploring the preliminary antitumour activity of combining binimetinib with Opdivo, and Opdivo plus Yervoy.

Results from this first study, which is anticipated to begin in the second half of 2017, will be used to determine optimal approaches for the further clinical development of these combinations.

Dr Fouad Namouni, head of oncology development at Bristol-Myers Squibb, said: "We are committed to investigating a wide range of oncology therapies, and look forward to studying the combination of Array's MEK inhibitor and our immunotherapies with the goal of developing more treatment options for patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.